New York, NY – June 3, 2014 – Bellicum Pharmaceuticals, Inc. announced today that Tom Farrell, Chief Executive Officer, will provide an update on the Company at the Jefferies 2014 Global Healthcare Conference in New York City. The presentation will take place today, Tuesday, June 3 from 9:00-9:30 AM EDT.

In the presentation, Mr. Farrell will review the Company’s two product platforms designed to strengthen a patient’s immune response to cancer, or reduce or eliminate cell-based treatments that put a patient’s health at risk. Bellicum is conducting Phase 1/2 clinical studies in leukemia and lymphoma and in prostate cancer. Bellicum is also collaborating with the National Cancer Institute (NCI) on a Phase 1 study with third generation CAR T cells modified with its CaspaCIDe^®cell therapy safety switch to treat solid tumors. More information can be found at www.bellicum.com

Jefferies Global Healthcare Conference is a four-day global meeting of leading company executives, as well as institutional private equity and venture capital investors, covering the near- and long-term investment themes, opportunities, and current drivers of the healthcare sector in the U.S. and internationally.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is dedicated to improving the treatment of cancers and other serious, life-threatening diseases with safer and more effective cell therapies. By giving physicians control over cells and immune activity inside the body, the Company’s Chemical Induction of Dimerization (CID) technology is designed to improve clinical outcomes while greatly expanding the numbers of patients who are eligible for treatment. For more information, visit www.bellicum.com.